Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Roche Kytril Acquisition From SmithKline Strengthens Hospital Focus In U.S.

  • News

Executive Summary

Roche's acquisition of the anti-emetic Kytril from SmithKline Beecham will build on Roche's strength in the U.S. hospital market.

You may also be interested in...



GSK Ad Campaign Highlights R&D Investment, “Orange Card”

GlaxoSmithKline is highlighting its investment in R&D in a national advertising campaign

GSK Ad Campaign Highlights R&D Investment, “Orange Card”

GlaxoSmithKline is highlighting its investment in R&D in a national advertising campaign

Pharma Faces Phase III Licensing Drought; Separate R&D “Pools” May Help

Pharmaceutical companies should separate R&D budgets for internal and external deals, Bayer Licensing & Acquisitions Associate Director Ann Kraft suggested

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

ACA Ruling Is Double Whammy For PrEP Coverage, With Contraception And Vaccines Still At Risk

The Power Of The Public: Isotretinoin iPLEDGE Advisory Cmte. Is Case Study In An Effective OPH

Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing

iPLEDGE REMS: US FDA Advisory Cmte. Supports Relaxing Restrictions But Wants More Data

See All
UsernamePublicRestriction

Register

PS036587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By